Lundbeck discontinues phase II study with schizophrenia drug

Following a series of disappointing clinical results, Lundbeck stops a phase II study with compound Lu AF11167 as a treatment for patients with schizophrenia who are experiencing persistent negative symptoms.

Photo: Martin Lehmann

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles